Clinical trials
Chronic Hepatitis clinical trials
Below are recruiting chronic hepatitis clinical trials, each written for real people, not researchers. We’re tracking 134 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02863757Recruiting
Follow-up study for chronic hepatitis B with fatty liver
This study follows people who have chronic hepatitis B and also have fat buildup in the liver (nonalcoholic fatty liver disease). It’s looking at how these conditions behave over time and what may help, using information collected during follow-up visits.
Hong Kong, Hong KongAges Any age - NCT03933384RecruitingPhase 4
Tenofovir alafenamide versus entecavir for chronic hepatitis B
This study compares two approved hepatitis B medicines—tenofovir alafenamide and entecavir—to see which works best for people with chronic hepatitis B. It may help improve control of the virus and support better long-term liver health.
Taichung, TaichungAges 20 years+ - NCT07370207RecruitingPhase 2
Study of AHB-137 for HBeAg negative chronic hepatitis B
This study tests a new medicine called AHB-137 for people with chronic hepatitis B who are HBeAg negative and currently on antiviral therapy. The goal is to see if it can help control the virus better or allow you to stop your current medication safely.
Fitzroy, VictoriaAges 18–65 - NCT05956379Enrolling by invitation
Exercise and monitoring study for chronic hepatitis B with fatty liver
This study follows adults with chronic hepatitis B who also have fatty liver and tests an exercise approach to see how it affects liver health. You may be followed over time and helped with an exercise plan if you qualify.
Taipei, Zhongzheng Dist.Ages 18–70 - NCT07090759RecruitingPhase 3
Test of new drug for hepatitis B not fully controlled by current treatment
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
Hangzhou, ZhejiangAges 18–70 - NCT07606950RecruitingPhase 3
Testing HRS-5635 to improve hepatitis B treatment
This study tests whether adding a new drug called HRS-5635 to your current hepatitis B medicine works better than your current treatment alone. You may qualify if your hepatitis B is already controlled with antiviral pills and your viral levels are very low.
Guangzhou, GuangzhouAges 18 years+ - NCT06368882RecruitingPhase 4
Peg-interferon for hepatitis B with fatty liver
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
NingboAges 18–60 - NCT05989958RecruitingPhase 1/Phase 2
HepaCure for acute-on-chronic liver failure
This trial tests a new treatment called HepaCure for people with acute-on-chronic liver failure (a sudden worsening of liver function in someone with long-term liver disease). The goal is to see if it is safe and can help improve liver function.
Beijing, Beijing MunicipalityAges 18–65 - NCT07654283RecruitingPhase 2
Study of AHB-137 for chronic hepatitis B
This trial tests a new drug, AHB-137, in people with chronic hepatitis B who are already on a stable antiviral treatment. It aims to see if AHB-137 can help lower the virus further or improve outcomes.
Palo Alto, CaliforniaAges 18–65 - NCT07069569RecruitingPhase 2
AHB-137 injection combined with other hepatitis B drugs
This study tests a new injection called AHB-137 combined with other hepatitis B drugs. It aims to see if the combination can better control the virus in people with chronic hepatitis B who are already on antiviral pills.
Beijing, Beijing MunicipalityAges 18–65 - NCT05856890RecruitingPhase 1
Test antibody treatment for chronic hepatitis B
This Phase 1 trial tests HepB mAb19, an antibody medicine, in adults with chronic hepatitis B. The goal is to see how it works and how safe it is in people whose hepatitis B is controlled on current antiviral treatment.
New York, New YorkAges 18–70 - NCT07179575RecruitingPhase 1/Phase 2
Study of LW231 for people with chronic hepatitis B
This trial tests a new drug, LW231, in people with chronic hepatitis B. It aims to see if the drug can reduce the amount of virus and surface antigen in your blood, and if it is safe for you.
Hangzhou, ZhejiangAges 18–60 - NCT07200193RecruitingPhase 1/Phase 2
Study of CRMA-1001 for chronic hepatitis B
This trial tests a new drug called CRMA-1001 in people with chronic hepatitis B who are already on antiviral therapy. The goal is to see if it can help control the virus better.
LyonAges 18–64 - NCT07741461RecruitingPhase 1
Testing ACT201 for chronic hepatitis B
This trial tests a new medication called ACT201 in two parts: one for healthy volunteers and one for people with chronic hepatitis B. For participants with hepatitis B, the drug may help control the infection, and the study will check its safety and how well it works.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06659588Recruiting
Study of chronic hepatitis risk in people with immune weaknesses
This study looks at people with certain immune system weaknesses to see if they are at risk for chronic hepatitis caused by a virus in the gut. Researchers want to understand how the immune system affects this infection.
ParisAges Any age - NCT06803368Recruiting
Recovery and maintenance strategies for chronic hepatitis B
This trial is for people with chronic hepatitis B who have already cleared the virus with interferon treatment. It tests ongoing strategies to help maintain their health and prevent the virus from coming back.
Beijing, Beijing MunicipalityAges 18–65 - NCT04310787Recruiting
Tracking outcomes in adults with hepatitis B liver failure
This study looks at long-term survival in people ages 18–65 who are hospitalized with hepatitis B–related acute-on-chronic liver failure. It may help doctors better predict prognosis and improve care for people with this serious condition.
Guangzhou, GuangdongAges 18–65 - NCT06887036RecruitingPhase 2
Methylene blue for chronic inactive hepatitis B
This trial tests whether a medication called methylene blue can help lower the amount of hepatitis B virus in people with a chronic but inactive infection. It may be an option for people whose virus levels are stable but not fully controlled.
Lugano, Canton TicinoAges 18–79 - NCT06513286RecruitingPhase 1/Phase 2
Therapeutic hepatitis B vaccine study using a two-part shot
This trial tests a new vaccine to treat chronic hepatitis B. It's for people who have been on antiviral medication for at least 6 months and still have a low level of the virus in their blood.
FrankfurtAges 18–70 - NCT07169656Recruiting
Study on reducing liver cancer risk in hepatitis B patients
This study looks at how well different hepatitis B treatments help lower the risk of liver cancer. It's for people with chronic hepatitis B who are already using or starting certain antiviral or interferon therapies.
AnyangAges 18 years+ - NCT05977283Recruiting
Follow-up study for people whose hepatitis B test improved
This study follows people with hepatitis B (HBV) blood tests that have improved over the last year. It aims to learn what happens after the hepatitis B surface antigen (HBsAg) goes down, and may help doctors better predict outcomes.
Guangzhou, GuangdongAges 18–65 - NCT07024641RecruitingPhase 1
Safety study of GIGA-2339 for chronic Hepatitis B
This study tests an experimental antibody (GIGA-2339) given as an infusion to people with chronic Hepatitis B. It aims to see if the drug is safe and how the body processes it, possibly helping to control the virus.
Chandler, ArizonaAges 18 years+ - NCT04914611Recruiting
Real-world study of chronic hepatitis B care in Australia
This study looks at people who have long-term hepatitis B and how they receive care in Australia. It may help improve understanding of what’s working in real life for patients like you.
Sydney, New South WalesAges 18 years+ - NCT05030571Recruiting
Plasma adsorption for adults with liver failure in the ICU
This trial studies a treatment called the Double Plasma Molecular Adsorption System (DPMAS) for people with acute-on-chronic liver failure while they are in the ICU. It aims to see whether filtering certain substances from blood can improve outcomes and safety for critically ill patients.
BangkokAges 18 years+
Hear when a new Chronic Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic hepatitis?
- Yes. Clin2 currently lists 134 recruiting chronic hepatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic hepatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic hepatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.